Roy René
Department of Chemistry, Université du Québec à Montréal, P.O. Box 8888, Succ. Centre-Ville, Montréal, Québec, Canada H3C 3P8.
Drug Discov Today Technol. 2004 Dec;1(3):327-36. doi: 10.1016/j.ddtec.2004.10.005.
Carbohydrate-based vaccines constitute successful therapeutic arsenals against microbial infections, particularly since the advent of bacterial capsular polysaccharide (CPS) protein conjugates. These prophylactic approaches are increasingly more accessible for other therapies such as viral, parasitic, fungal infections and even against certain forms of cancer. Three major discoveries are responsible for rapid growth in this field. In the first instance, the recent commercialization of the first semi-synthetic vaccine against bacterial infections caused by Haemophilus influenza type b, second by the rapid access to complex saccharide structures through one-pot, solution-phase syntheses, and third by automated solid-phase synthesis.:
基于碳水化合物的疫苗是对抗微生物感染的成功治疗手段，尤其是自细菌荚膜多糖（CPS）蛋白偶联物问世以来。这些预防方法在其他治疗中越来越容易获得，如病毒、寄生虫、真菌感染，甚至对抗某些形式的癌症。该领域的快速发展得益于三项重大发现。首先，第一种针对b型流感嗜血杆菌引起的细菌感染的半合成疫苗最近实现了商业化；其次，通过一锅法溶液相合成能够快速获得复杂的糖结构；第三，实现了自动化固相合成。
